Core Viewpoint - Sanofi Pharmaceutical-B (02257) has seen a significant stock price increase of over 530% this year, with a current price of HKD 22.12 and a trading volume of HKD 33.0162 million [2] Group 1: Stock Performance - Sanofi Pharmaceutical's stock rose by over 9% during the trading session, reflecting strong market interest [2] - The stock has accumulated a year-to-date increase of over 530% [2] Group 2: Investment and Strategic Partnerships - Sanofi Pharmaceutical announced a placement of 17.3524 million new shares at a discount of 19.84% to four investors, including Huaxi Biotechnology (Hong Kong) [2] - Huaxi Biotechnology plans to invest approximately CNY 138 million to acquire shares in Sanofi Pharmaceutical, resulting in a 9.44% ownership stake post-placement [2] - The investment by Huaxi Biotechnology aims to advance Sanofi Pharmaceutical's research and commercialization in the fields of medical aesthetics, aging intervention, and regenerative medicine, particularly focusing on the STP705 targeted fat reduction project and other siRNA-based medical aesthetic assets [2]
圣诺医药-B盘中涨超9% 本年内股价累计涨幅已超530%